CA3132827A1 - Method for treating female non-smokers with non-small cell lung cancer - Google Patents
Method for treating female non-smokers with non-small cell lung cancer Download PDFInfo
- Publication number
- CA3132827A1 CA3132827A1 CA3132827A CA3132827A CA3132827A1 CA 3132827 A1 CA3132827 A1 CA 3132827A1 CA 3132827 A CA3132827 A CA 3132827A CA 3132827 A CA3132827 A CA 3132827A CA 3132827 A1 CA3132827 A1 CA 3132827A1
- Authority
- CA
- Canada
- Prior art keywords
- lung cancer
- small cell
- cell lung
- patient
- dithio
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epoxy Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962815762P | 2019-03-08 | 2019-03-08 | |
| US62/815,762 | 2019-03-08 | ||
| PCT/US2020/021615 WO2020185640A1 (en) | 2019-03-08 | 2020-03-08 | Method for treating female non-smokers with non-small cell lung cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3132827A1 true CA3132827A1 (en) | 2020-09-17 |
Family
ID=72427123
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3132827A Pending CA3132827A1 (en) | 2019-03-08 | 2020-03-08 | Method for treating female non-smokers with non-small cell lung cancer |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220168258A1 (https=) |
| EP (1) | EP3935043A4 (https=) |
| JP (2) | JP2022525040A (https=) |
| KR (1) | KR20220047208A (https=) |
| CN (2) | CN113906010A (https=) |
| AU (2) | AU2020235823A1 (https=) |
| BR (1) | BR112021017716A2 (https=) |
| CA (1) | CA3132827A1 (https=) |
| MX (1) | MX2021010745A (https=) |
| SG (1) | SG11202109705YA (https=) |
| WO (1) | WO2020185640A1 (https=) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2008352597B2 (en) * | 2008-03-14 | 2012-03-08 | Bionumerik Pharmaceuticals, Inc. | Treatment methods and compositions for lung cancer, adenocarcinoma, and other medical conditions |
| JP5667886B2 (ja) * | 2008-03-14 | 2015-02-12 | バイオニューメリック・ファーマスーティカルズ・インコーポレイテッド | 癌患者の生存時間を増大させるための組成物及び化合物の使用方法 |
| CA2717915A1 (en) * | 2008-03-14 | 2009-09-17 | Bionumerik Pharmaceuticals, Inc. | Chemoprotective methods and compositions |
| US20170007561A1 (en) * | 2014-08-08 | 2017-01-12 | Bionumerik Pharmaceuticals, Inc. | Contemporaneous, heterogeneously-oriented, multi-targeted therapeutic modification and/or modulation of disease by administration of sulfur-containing, amino acid-specific small molecules |
-
2020
- 2020-03-08 EP EP20770472.7A patent/EP3935043A4/en active Pending
- 2020-03-08 JP JP2021553070A patent/JP2022525040A/ja active Pending
- 2020-03-08 MX MX2021010745A patent/MX2021010745A/es unknown
- 2020-03-08 AU AU2020235823A patent/AU2020235823A1/en not_active Abandoned
- 2020-03-08 CN CN202080034238.XA patent/CN113906010A/zh active Pending
- 2020-03-08 KR KR1020217031523A patent/KR20220047208A/ko not_active Ceased
- 2020-03-08 SG SG11202109705Y patent/SG11202109705YA/en unknown
- 2020-03-08 BR BR112021017716A patent/BR112021017716A2/pt unknown
- 2020-03-08 CA CA3132827A patent/CA3132827A1/en active Pending
- 2020-03-08 CN CN202510278250.XA patent/CN120078760A/zh active Pending
- 2020-03-08 WO PCT/US2020/021615 patent/WO2020185640A1/en not_active Ceased
-
2021
- 2021-09-08 US US17/469,765 patent/US20220168258A1/en not_active Abandoned
-
2025
- 2025-01-27 JP JP2025011556A patent/JP2025081338A/ja active Pending
- 2025-11-12 AU AU2025267367A patent/AU2025267367A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022525040A (ja) | 2022-05-11 |
| EP3935043A4 (en) | 2023-01-11 |
| JP2025081338A (ja) | 2025-05-27 |
| BR112021017716A2 (pt) | 2021-11-16 |
| MX2021010745A (es) | 2021-12-15 |
| US20220168258A1 (en) | 2022-06-02 |
| EP3935043A1 (en) | 2022-01-12 |
| AU2020235823A1 (en) | 2021-11-04 |
| WO2020185640A1 (en) | 2020-09-17 |
| AU2025267367A1 (en) | 2025-12-04 |
| KR20220047208A (ko) | 2022-04-15 |
| CN120078760A (zh) | 2025-06-03 |
| SG11202109705YA (en) | 2021-10-28 |
| CN113906010A (zh) | 2022-01-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Monnet et al. | Phase II study of oxaliplatin in poor-prognosis non-small cell lung cancer (NSCLC) | |
| CN117377476B (zh) | 治疗与化学疗法诱发的周围神经病变相关的疼痛 | |
| CN111184863B (zh) | 酪氨酸激酶抑制剂、cdk4/6抑制剂、serd联合在制备治疗肿瘤的药物中的用途 | |
| US9381246B2 (en) | Cancer therapy | |
| AU2015317856B2 (en) | Veliparib in combination with carboplatin and paclitaxel for the treatment of non-small cell lung cancer in smokers | |
| Zhou et al. | Coronarin D suppresses proliferation, invasion and migration of glioma cells via activating JNK signaling pathway | |
| US20220168258A1 (en) | Method for treating female non-smokers with non-small cell lung cancer | |
| CA3134156C (en) | Chiauranib for treatment of small cell lung cancer | |
| CN111249465A (zh) | Topk作为宫颈癌顺铂耐药治疗靶点的应用 | |
| EP3302472A1 (de) | Biperiden zur behandlung von krebs | |
| EP3752154A1 (en) | Methods and combination therapy to treat biliary tract cancer | |
| CN110787173A (zh) | 化合物在制备治疗多药耐药性癌症的药物的应用 | |
| Gent et al. | An overview of chemotherapy-induced peripheral sensory neuropathy, focusing on oxaliplatin | |
| JP2020512408A (ja) | 肺がんの治療に使用するための組み合わせ | |
| JP2008169220A (ja) | 癌を処置または予防するためのβ−ラパコンの使用 | |
| CN106038571B (zh) | 一种含小分子靶向药物吉非替尼的药物组合物及其在制备抗肿瘤药物中的应用 | |
| WO2025137692A1 (en) | Combination of dimesna and pemetrexed to treat non-small cell lung cancer (nsclc) | |
| CN111718328A (zh) | 4-甲基-1h-二芳基吡唑类衍生物在制备抗肿瘤药物中的用途 | |
| US20230172872A1 (en) | Use of an rxr agonist and taxanes in treating her2+ cancers | |
| TWI858861B (zh) | Bet抑制劑及parp抑制劑於治療胰臟癌之用途 | |
| JP2013510126A (ja) | コリン含有医薬組成物 | |
| Ross | Lung Tumorigenesis | |
| TW202339753A (zh) | 用於與抗癌藥物共同投與之包含酞嗪酮衍生物之醫藥組合物 | |
| Lorusso et al. | Topotecan plus ifosfamide in patients with platinum refractory advanced/metastatic non-small cell lung cancer: a phase II trial | |
| Yang et al. | JAB-2485: a potent, highly selective small-molecule Aurora Kinase A inhibitor that targets cell division |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20240307 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250120 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250120 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250120 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250221 |
|
| R00 | Party data change recorded |
Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R00-R116 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPOINTMENT OF AGENT REQUEST Effective date: 20250620 Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R00-R119 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUEST Effective date: 20250620 |
|
| T11 | Administrative time limit extension requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-T10-T11-T100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXTENSION OF TIME FOR TAKING ACTION REQUEST RECEIVED Effective date: 20250620 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250702 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250820 |
|
| R17 | Change to representative recorded |
Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R17-R121 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260124 Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R17-R117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPOINTMENT OF AGENT REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260124 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260124 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260212 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260212 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260212 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260220 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260220 |
|
| T13 | Administrative time limit extension granted |
Free format text: ST27 STATUS EVENT CODE: A-2-2-T10-T13-T101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXTENSION OF TIME FOR TAKING ACTION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260331 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260331 |